Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mark Till is active.

Publication


Featured researches published by Mark Till.


Cellular Immunology | 1989

The epitope specificity and tissue reactivity of four murine monoclonal anti-CD22 antibodies☆

Jia Ling Li; Guo Liang Shen; Maria Ana Ghetie; Richard D. May; Mark Till; Victor Ghetie; Jonathan W. Uhr; George Janossy; Philip E. Thorpe; Peter Amlot; Ellen S. Vitetta

The CD22 antigen is expressed on the surface of normal human B cells and some neoplastic B cell lines and tumors. Previous cross-blocking studies using a panel of monoclonal anti-CD22 antibodies have defined four epitope groups, termed A-D. In the present studies, we have further dissected the epitopes recognized by four monoclonal anti-CD22 antibodies using immunoprecipitation and cross-blocking techniques, immunofluorescence analyses with a variety of cell lines, and immunoperoxidase analyses of 36 normal human tissues. Two of the antibodies, HD6 and RFB4, have been described previously, and two, UV22-1 and UV22-2, are described in this report. Our studies indicate that the four monoclonal antibodies show unexpected complexities in their reactivity with CD22+ and CD22- cells and their reactivity with solubilized CD22 molecules. The four antibodies, which recognize epitopes defined previously as CD22-A and CD22-B, further subdivide these epitope clusters into four determinants, A1, A2, B1, and B2. Furthermore, only two of the antibodies, RFB4 and UV22-2, are B cell-specific. In summary, our data indicate that RFB4 and UV22-2 would be the antibodies of choice for constructing immunotoxins to treat B cell tumors.


Journal of Immunological Methods | 1990

Large scale preparation of an immunoconjugate constructed with human recombinant CD4 and deglycosylated ricin A chain

Victor Ghetie; Mark Till; Maria-Ana Ghetie; Jonathan W. Uhr; Ellen S. Vitetta

A method for the preparation and purification of large amounts (grams) of a conjugate containing recombinant CD4 antigen (rCD4) and chemically deglycosylated ricin A chain (dgA) is described. The cross-linking of rCD4 and dgA molecules was accomplished with N-succinimidyl-oxycarbonyl-alpha-methyl-(2-pyridyldithio)toluene (SMPT). The rCD4-dgA conjugate was purified by an automatic liquid chromatography system consisting of Blue-Sepharose CL-4B and Sephacryl S-200HR Pharmacia Bioprocess columns. The purified, endotoxin-free rCD4-dgA conjugate had a stable (hindered) disfulfide bond between rCD4 and dgA and was able to efficiently kill a human T cell line infected with HIV-1.


Science | 1987

Redesigning nature's poisons to create anti-tumor reagents

Ellen S. Vitetta; Rj Fulton; Rd May; Mark Till; J W Uhr


Cancer Research | 1991

Phase I immunotoxin trial in patients with B-cell lymphoma

Ellen S. Vitetta; Marvin J. Stone; Peter Lloyd Amlot; Joseph W. Fay; Richard D. May; Mark Till; Joe Newman; Patty Clark; Robert D. Collins; David Cunningham; Victor Ghetie; Jonathan W. Uhr; Philip E. Thorpe


Cancer Research | 1988

Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy

Maria-Ana Ghetie; Richard D. May; Mark Till; Jonathan W. Uhr; Victor Ghetie; Phillip P. Knowles; Michele Relf; Alex Brown; Philip M. Wallace; George Janossy; Peter Amlot; Ellen S. Vitetta; Philip E. Thorpe


Science | 1988

HIV-infected cells are killed by rCD4-ricin A chain.

Mark Till; Victor Ghetie; Timothy J. Gregory; Eric J. Patzer; James P. Porter; Jonathan W. Uhr; Daniel J. Capon; Ellen S. Vitetta


International Journal of Cancer | 1988

Evaluation of four CD22 antibodies as ricin a chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas

Guo-Liang Shen; Jia-Ling Li; Maria-Ana Ghetie; Victor Ghetie; Richard D. May; Mark Till; Alex N. F. Brown; Michele G. Relf; Phillip P. Knowles; Jonathan W. Uhr; George Janossy; Peter Amlot; Ellen S. Vitetta; Philip E. Thorpe


Cancer Research | 1988

An Assay That Predicts the Ability of Monoclonal Antibodies to Form Potent Ricin A Chain-containing Immunotoxins

Mark Till; Richard D. May; Jonathan W. Uhr; Philip E. Thorpe; Ellen S. Vitetta


Proceedings of the National Academy of Sciences of the United States of America | 1989

Human immunodeficiency virus-infected T cells and monocytes are killed by monoclonal human anti-gp41 antibodies coupled to ricin A chain

Mark Till; Zolla-Pazner S; M K Gorny; J S Patton; J W Uhr; Ellen S. Vitetta


Bioconjugate Chemistry | 1990

Preparation and characterization of conjugates of recombinant CD4 and deglycosylated ricin A chain using different cross-linkers.

Victor Ghetie; Mark Till; Maria Ana Ghetie; Thomas F. Tucker; James P. Porter; Eric J. Patzer; James A. Richardson; Jonathan W. Uhr; Ellen S. Vitetta

Collaboration


Dive into the Mark Till's collaboration.

Top Co-Authors

Avatar

Ellen S. Vitetta

University of Texas Southwestern Medical Center

View shared research outputs
Top Co-Authors

Avatar

Jonathan W. Uhr

University of Texas Southwestern Medical Center

View shared research outputs
Top Co-Authors

Avatar

Victor Ghetie

University of Texas Southwestern Medical Center

View shared research outputs
Top Co-Authors

Avatar

Richard D. May

University of Texas Southwestern Medical Center

View shared research outputs
Top Co-Authors

Avatar

Philip E. Thorpe

University of Texas Southwestern Medical Center

View shared research outputs
Top Co-Authors

Avatar

J W Uhr

University of Texas Health Science Center at San Antonio

View shared research outputs
Top Co-Authors

Avatar

Maria-Ana Ghetie

University of Texas Southwestern Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge